These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

349 related items for PubMed ID: 21041299

  • 41.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 42. Thrombin activatable fibrinolysis inhibitor (TAFI): a molecular link between coagulation and fibrinolysis.
    Miljić P, Heylen E, Willemse J, Djordjević V, Radojković D, Colović M, Elezović I, Hendriks D.
    Srp Arh Celok Lek; 2010 Jan; 138 Suppl 1():74-8. PubMed ID: 20229688
    [Abstract] [Full Text] [Related]

  • 43. Secretion and antifibrinolytic function of thrombin-activatable fibrinolysis inhibitor from human platelets.
    Schadinger SL, Lin JH, Garand M, Boffa MB.
    J Thromb Haemost; 2010 Nov; 8(11):2523-9. PubMed ID: 20723026
    [Abstract] [Full Text] [Related]

  • 44. Deficiency of thrombin activatable fibrinolysis inhibitor in cirrhosis is associated with increased plasma fibrinolysis.
    Colucci M, Binetti BM, Branca MG, Clerici C, Morelli A, Semeraro N, Gresele P.
    Hepatology; 2003 Jul; 38(1):230-7. PubMed ID: 12830006
    [Abstract] [Full Text] [Related]

  • 45.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 46.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 47.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 48. Demonstration of enhanced endogenous fibrinolysis in thrombin activatable fibrinolysis inhibitor-deficient mice.
    Mao SS, Holahan MA, Bailey C, Wu G, Colussi D, Carroll SS, Cook JJ.
    Blood Coagul Fibrinolysis; 2005 Sep; 16(6):407-15. PubMed ID: 16093731
    [Abstract] [Full Text] [Related]

  • 49.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 50. Generation and characterization of inhibitory nanobodies towards thrombin activatable fibrinolysis inhibitor.
    Buelens K, Hassanzadeh-Ghassabeh G, Muyldermans S, Gils A, Declerck PJ.
    J Thromb Haemost; 2010 Jun; 8(6):1302-12. PubMed ID: 20180900
    [Abstract] [Full Text] [Related]

  • 51. Does an enzyme other than thrombin contribute to unexpected changes in the levels of the different forms of thrombin activatable fibrinolysis inhibitor in patients with hemophilia A, hemophilia B and von Willebrand disease?
    Antovic JP, Schulman S, An SS, Greenfield RS, Blombäck M.
    Scand J Clin Lab Invest; 2004 Jun; 64(8):745-51. PubMed ID: 15719893
    [Abstract] [Full Text] [Related]

  • 52. [Regulatory mechanism of fibrinolysis system by thrombin activatable fibrinolysis inhibitor (TAFI)].
    Urano T.
    Nihon Yakurigaku Zasshi; 2000 Nov; 116(5):298-303. PubMed ID: 11215380
    [Abstract] [Full Text] [Related]

  • 53. Thrombin activatable fibrinolysis inhibitor and an antifibrinolytic pathway.
    Bajzar L.
    Arterioscler Thromb Vasc Biol; 2000 Dec; 20(12):2511-8. PubMed ID: 11116046
    [Abstract] [Full Text] [Related]

  • 54. Factor XI dependent and independent activation of thrombin activatable fibrinolysis inhibitor (TAFI) in plasma associated with clot formation.
    Bouma BN, Mosnier LO, Meijers JC, Griffin JH.
    Thromb Haemost; 1999 Dec; 82(6):1703-8. PubMed ID: 10613658
    [Abstract] [Full Text] [Related]

  • 55. Generation of a stable activated thrombin activable fibrinolysis inhibitor variant.
    Ceresa E, Van de Borne K, Peeters M, Lijnen HR, Declerck PJ, Gils A.
    J Biol Chem; 2006 Jun 09; 281(23):15878-83. PubMed ID: 16595693
    [Abstract] [Full Text] [Related]

  • 56. Thrombin, thrombomodulin and TAFI in the molecular link between coagulation and fibrinolysis.
    Nesheim M, Wang W, Boffa M, Nagashima M, Morser J, Bajzar L.
    Thromb Haemost; 1997 Jul 09; 78(1):386-91. PubMed ID: 9198184
    [Abstract] [Full Text] [Related]

  • 57. A case of thrombomodulin mutation causing defective thrombin binding with absence of protein C and TAFI activation.
    Okada M, Tominaga N, Honda G, Nishioka J, Akita N, Hayashi T, Suzuki K, Moriuchi H.
    Blood Adv; 2020 Jun 23; 4(12):2631-2639. PubMed ID: 32556284
    [Abstract] [Full Text] [Related]

  • 58. Characterization of thrombin activatable fibrinolysis inhibitor in normal and acquired haemostatic dysfunction.
    Toh CH.
    Blood Coagul Fibrinolysis; 2003 Jun 23; 14 Suppl 1():S69-71. PubMed ID: 14567541
    [Abstract] [Full Text] [Related]

  • 59.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 60.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 18.